Emerson Reports Fourth Quarter and Full Year 2026 Results; Provides Initial 2027 Outlook

Emerson reported FY2026 net sales of $18.982B, up 5%, and adjusted EPS of $6.59, up 10%; Q4 adjusted EPS rose 15% to $1.86, while adjusted segment EBITA margin expanded 160bps to 29.1%. For FY2027, it forecast approximately 5% sales growth and adjusted EPS of about $7.25, and expects to return approximately $3.8B through $2.5B of share repurchases and $1.3B of dividends. The company also raised its quarterly dividend 7% to $0.595 per share.

Analysis

The better signal is the divergence between 4% FY26 underlying sales growth and 10% adjusted EPS growth: execution and mix are adding leverage, but FY27’s ~10% adjusted EPS growth against ~5% sales growth also appears to rely on continued margin gains and share-count reduction. That makes delivery—not the secular-automation narrative—the key underwriting test. Software & Systems and Test & Measurement are the strongest apparent demand/mix contributors; weaker growth in Sensors, Final Control and Safety & Productivity limits the case for a uniformly accelerating cycle. Order quality matters: management cites 14% underlying order growth, while the release’s headline table appears to show 9% for FY26 Q4 (and 14% for the prior-year quarter). Resolve this discrepancy on the call before treating bookings as acceleration. Long-cycle projects can support backlog visibility but also defer revenue conversion and carry cancellation/timing risk. Capital returns are close to projected FY27 free cash flow, leaving little of that cash-flow envelope for incremental debt reduction or flexibility; verify planned borrowing, buyback cadence, and backlog conversion. Near term, the call may drive reaction to guidance and the orders inconsistency. Over 1–3 months, track quarterly book-to-bill/backlog conversion and margin delivery; over 6–18 months, the thesis depends on sustained software/project demand and operating leverage. The contrarian risk is that investors capitalize adjusted EPS growth while discounting the gap between GAAP and adjusted earnings, including recurring amortization. No valuation or consensus data here establishes that EMR is cheap or that the initial reaction is mispriced.

Key Decisions for Investors

• Do not chase before the conference call. Ask management to reconcile the 9% versus 14% Q4 underlying-order figures and clarify whether the FY27 EPS bridge depends on margin expansion, repurchases, or both.
• Conditional trade: if the call confirms order growth and backlog conversion without weakening FY27 guidance, consider a measured long EMR versus XLI, sized as a quality/earnings-delivery position rather than a pure cyclical-upside bet. Reassess if subsequent underlying sales or adjusted segment margins miss the trajectory implied by guidance.
• Treat the ~$3.8B capital-return plan as a cash-allocation constraint, not an automatic valuation catalyst: monitor repurchase execution, net debt and interest expense. Falsify the supportive view if buybacks require materially more borrowing or cash conversion deteriorates.
• Watch the reported-to-adjusted earnings bridge and working capital: recurring adjustments or renewed inventory/receivables cash absorption would weaken confidence in the headline EPS and free-cash-flow growth.